2-methoxyestradiol
Recurrent Glioblastoma Multiforme
CASI pharmaceuticals, Inc.Small moleculePhase 2Dormant
B
62/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 47/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Recurrent Glioblastoma Multiforme cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
tp38 Teva Branded Pharmaceutical Products R&D, Inc. | Phase 2 | B |
Buparlisib Novartis Pharmaceuticals | Phase 1/2 | CCC |
Procarbazine Incheon St.Mary's Hospital | Phase 2 | CCC |
Snc-109 Car-T Cells Shanghai Simnova Biotechnology Co.,Ltd. | Phase 1 | CC |
Rta 744 WPD Pharmaceuticals Sp. z o.o. | Phase 1/2 | C |
Same molecule, other indications
2-methoxyestradiol is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →